Overall, network pharmacology analysis suggests that EMP may exert its therapeutic effects on HUA‐CI through multi‐target and multi‐pathway mechanisms, particularly by modulating key targets like MAP2K1, with AF being a primary active component. The gene discussed is MAP2K1; the disease is atrial fibrillation.